Medication info

Rostel Plus Tablet 80/5/5 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium Micronized›5.2mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
Oval-shaped two-layer tablet consisting of a white layer and a light blue layer
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202302814 · Approved 2023.09.25

Summary

Main use
Treatment of dyslipidemia and hypertension, and inhibition of atherosclerotic progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
This medicine should be taken once daily as 1 tablet with water, regardless of meals. If possible, it is recommended that it be taken at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. However, in patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older adults: In patients 75 years of age or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and should continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 mg once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, rosuvastatin Cmax increased approximately 2.1-fold and AUC increased approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia and hypertension, and inhibition of atherosclerotic progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • and family history of premature coronary heart disease.
View approved original text

This medication is used for patients with essential hypertension who have difficulty controlling blood pressure when using telmisartan and amlodipine alone. Additionally, rosuvastatin acts as an adjunct to dietary therapy for patients with hypercholesterolemia and dyslipidemia, helping to lower total cholesterol and LDL cholesterol levels, thereby delaying the progression of atherosclerosis. It is particularly effective in reducing the risks associated with stroke, myocardial infarction, and arterial revascularization in middle-aged patients at high risk for cardiovascular diseases. Therefore, this medication is used to effectively manage blood pressure and lipid levels.

How to take

Adult dose

This medicine should be taken once daily as 1 tablet with water, regardless of meals. If possible, it is recommended that it be taken at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. However, in patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older adults: In patients 75 years of age or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and should continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 mg once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, rosuvastatin Cmax increased approximately 2.1-fold and AUC increased approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This medication may cause serious harm to the fetus and newborn during pregnancy; therefore, if pregnancy is confirmed, it should be discontinued immediately. Patients with allergies to the components of this medication or similar drugs should not use it. Patients with severe liver or kidney impairment, those with a history of angioedema, or specific heart disease patients should use this medication with caution. This medication should also be administered cautiously to elderly patients or those with very low blood pressure or elevated potassium levels. If symptoms such as muscle pain or muscle weakness occur, immediate consultation with a physician is necessary, and blood tests may be required to assess for muscle damage. This medication can affect liver function; therefore, liver function tests should be conducted regularly before and during treatment. Interactions may occur when taken with other medications, so it is essential to inform the physician or pharmacist about any other medications being taken. Pregnant or breastfeeding women should not take this medication, and women of childbearing potential should use appropriate contraceptive methods. Use in pediatric patients is not recommended as safety and efficacy have not been sufficiently established. In case of overdose, symptoms such as lowered blood pressure, dizziness, and muscle abnormalities may occur, requiring immediate medical attention. This medication should be kept out of reach of children and should not be transferred to other containers for safety.

Side effects

  • Peripheral edema
  • dyspepsia
  • frequent bowel movements
  • diabetes mellitus
  • dizziness
  • dry bulla sound
  • urticaria
  • unstable angina
  • onychomycosis
  • lumbar spinal canal stenosis
Show 249 more
  • ear discharge
  • vertigo
  • chronic gastritis
  • various gastrointestinal disorders
  • hiatus hernia
  • dysuria
  • rhinitis
  • discomfort in the oropharynx
  • lung disease
  • unspecified intestinal disease
  • benign gastrointestinal neoplasm
  • hemorrhoids
  • skeletal pain
  • osteoporosis
  • sensory loss
  • movement disorder
  • atherosclerosis
  • frequent urination
  • tinnitus
  • hearing loss
  • halitosis
  • fatty liver
  • upper respiratory tract infection
  • low back pain
  • sinusitis
  • diarrhea
  • pharyngitis
  • influenza-like symptoms
  • dyspepsia
  • myalgia
  • urinary tract infection
  • abdominal pain
  • headache
  • dizziness
  • pain
  • fatigue
  • cough
  • hypertension
  • chest pain
  • nausea
  • palpitations
  • dependency edema
  • angina
  • rapid pulse
  • leg edema
  • abnormal ECG
  • insomnia
  • drowsiness
  • migraine
  • dizziness
  • sensory abnormalities
  • involuntary muscle contractions
  • sensory loss
  • flatulence
  • constipation
  • gastritis
  • vomiting
  • dry mouth
  • hemorrhoids
  • gastroenteritis
  • enteritis
  • gastroesophageal reflux
  • toothache
  • non-specific gastrointestinal disease
  • gout
  • hypercholesterolemia
  • diabetes
  • arthritis
  • arthralgia
  • leg numbness
  • anxiety
  • depression
  • irritability
  • infection
  • fungal infection
  • abscess
  • otitis media
  • asthma
  • bronchitis
  • rhinitis
  • dyspnea
  • epistaxis
  • dermatitis
  • rash
  • eczema
  • itching
  • frequent urination
  • cystitis
  • cerebrovascular disease
  • visual disturbances
  • conjunctivitis
  • ear pain
  • vascular edema
  • fever
  • leg pain
  • malaise
  • headache
  • dizziness
  • asthenia
  • cough
  • nausea
  • fatigue
  • weakness
  • edema
  • facial swelling
  • lower limb edema
  • vascular edema
  • itching
  • hypersensitivity reaction
  • increased sweating
  • erythema
  • chest pain
  • atrial fibrillation
  • congestive heart failure
  • myocardial infarction
  • increased blood pressure
  • worsening hypertension
  • hypotension
  • hyperkalemia
  • hypoglycemia
  • syncope
  • dyspepsia
  • diarrhea
  • urinary tract infection
  • erectile dysfunction
  • muscle cramps
  • myalgia
  • bradycardia
  • eosinophilia
  • thrombocytopenia
  • increased uric acid
  • liver dysfunction
  • liver disease
  • acute renal failure
  • anemia
  • increased CPK
  • anaphylactic reaction
  • tendon pain
  • rhabdomyolysis
  • vascular edema
  • headache
  • edema
  • dizziness
  • flushing
  • palpitations
  • arrhythmia
  • bradycardia
  • chest pain
  • peripheral ischemia
  • syncope
  • orthostatic hypotension
  • vasculitis
  • peripheral neuropathy
  • tremors
  • dysphagia
  • pancreatitis
  • gingival hyperplasia
  • allergic reaction
  • burning sensation
  • malaise
  • rigidity
  • weight gain
  • weight loss
  • sexual dysfunction
  • insomnia
  • irritability
  • abnormal dreams
  • depersonalization
  • dyspnea
  • vascular edema
  • erythema multifforme
  • rash
  • erythematous rash
  • papular rash
  • vascular edema
  • skin depigmentation
  • dry skin
  • hair loss
  • dermatitis
  • muscle weakness
  • single contraction
  • ataxia
  • hypertonicity
  • migraine
  • cold and damp skin
  • apathy
  • amnesia
  • gastritis
  • increased appetite
  • loose stool
  • rhinitis
  • urinary disorders
  • polyuria
  • abnormal olfaction
  • taste disorders
  • abnormal ocular control
  • dry eyes
  • gynecomastia
  • jaundice
  • elevated liver enzyme levels
  • leukopenia
  • confusion
  • exfoliative dermatitis
  • Stevens-Johnson syndrome
  • phototoxic reaction
  • toxic epidermal necrolysis
  • myopathy
  • myositis
  • asthenia
  • constipation
  • nausea
  • abdominal pain
  • pancreatitis
  • itching
  • rash
  • urticaria
  • myalgia
  • rhabdomyolysis
  • asthenia
  • vascular edema
  • diabetes
  • headache
  • dizziness
  • constipation
  • nausea
  • abdominal pain
  • myalgia
  • myopathy
  • rhabdomyolysis
  • increased ALT
  • increased CK
  • increased AST
  • asthenia
  • joint pain
  • fatigue
  • numbness
  • sensory abnormalities
  • chest discomfort
  • anorexia
  • abdominal bloating
  • syncope
  • generalized pain
  • muscle cramps
  • gout
  • erectile dysfunction
  • acute renal failure
  • oliguria
  • thrombocytopenia
  • increased serum creatinine.

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light; therefore, it should be stored in a container that does not allow light to pass through. Additionally, it is advisable to keep it at a temperature ranging from 1 degree to 30 degrees Celsius at room temperature. Proper storage will help maintain the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Oval-shaped two-layer tablet consisting of a white layer and a light blue layer

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.